Continuous Intrathecal Baclofen Infusion for Chronic Spasticity
Information source: Flowonix Medical
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Spasticity
Intervention: Prometra Programmable Implantable Pump System (Device)
Phase: Phase 3
Status: Withdrawn
Sponsored by: Flowonix Medical Official(s) and/or principal investigator(s): Robert Levy, MD, PhD, Principal Investigator, Affiliation: Northwestern University Hospital
Summary
The purpose of this clinical investigation is to demonstrate product performance of the
Prometra Programmable Pump System in the delivery of intrathecal Lioresal® (baclofen) for
the management of severe spasticity.
Clinical Details
Official title: Continuous Intrathecal Baclofen Infusion for the Management of Chronic Spasticity
Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: The primary endpoint is: A change in the average lower extremity spasticity score as measured by the Modified Ashworth Scale
Secondary outcome: Secondary Endpoints include: Change in overall spasm frequency as measured by the Penn Spasm Frequency Scale. Change in overall Quality of Life as measured by the SF 36 and PSQI. SAE-free survival. DRAE-free survival. Tabulation of device complications.
Detailed description:
The Prometra Programmable Pump is a battery-operated, implantable, programmable infusion
pump that dispenses drug solution into the intrathecal space through an implanted infusion
catheter. All functions of the system (e. g., dosing) are controlled externally using a
hand-held, battery-operated programmer. Lioresal Intrathecal (baclofen) is indicated for use
in the management of severe spasticity. Spasticity is a major problem that has long
challenged traditional medical treatment. While the incidence of spasticity is not known
with certainty, it likely affects over half a million people in the United States and over
12 million worldwide. Spasticity is associated with some very common neurological disorders
such as: multiple sclerosis, stroke, cerebral palsy, spinal cord and brain injuries. Chronic
spasticity seriously restricts normal daily activities and reduces the quality of life for
many patients.
Eligibility
Minimum age: 22 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
The overall goal of this study is to choose patients most likely to experience therapeutic
success while reducing the likelihood of risks, complications and adverse events.
Patients meeting all of the following criteria will be eligible for enrollment in the
study:
1. Patient with a history of severe chronic spastic hypertonia in the lower extremities
lasting at least 6 months who:
- fail to respond to maximum recommended doses of antispasmodic medications
including baclofen, or
- those who experience intolerable CNS side effects at effective oral doses
2. Patient is >21 years of age
3. Patient, or legally authorized representative (LAR), has provided written informed
consent to participate in the study
4. Investigator considers the patient willing and able to fulfill all study requirements
5. Investigator has documented attempts to eliminate factors that can contribute to an
increase in spasticity (e. g. infection)
6. Patient has had a successful trial of Lioresal® for the management of the target
spasticity.
Exclusion Criteria:
Patients meeting any of the following criteria are to be excluded from the study:
1. Patient has MRI of the spine documenting structural abnormality preventing adequate
CSF flow. (If the patient has a medical condition that contraindicates screening MRI,
the investigator should proceed with the closest appropriate study i. e. CT scan,
X-ray, to rule out any spinal abnormalities that would prevent intrathecal drug
administration.)
2. Patient's anatomy is not large enough to accommodate the pump's size and weight.
3. Patient has a systemic infection.
4. Patient has renal insufficiency as evidenced by a baseline serum creatinine of >2. 0
mg/dl.
5. Patient has a history of a bleeding disorder.
6. Patient has a history of blood clots such as deep vein thrombosis (DVT) or pulmonary
embolism (PE) within 1 year of enrollment.
7. Patient is pregnant or breast-feeding, or is of child-bearing potential and not
employing effective birth control.
8. Patient has known allergies or sensitivities to pump system materials (e. g., silicone
rubber, titanium, polyphenylsulfone, acetal resin, polyvinylidene fluoride,
tungsten).
9. Patient has known allergies to Lioresal® (baclofen), or would be contraindicated for
Lioresal® based on the drug labeling.
10. Patient has other implantable electronic cardiac devices (i. e. pacemaker,
defibrillator, CRT system)
11. Patient has an occupation where he/she would be exposed to high current industrial
equipment, powerful magnets or transmitting towers, such as, electricians, electrical
engineers or MRI technicians.
12. Patient is participating in another clinical trial.
Locations and Contacts
Additional Information
Starting date: January 2010
Last updated: March 5, 2015
|